2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2788

Suppression of IL-1 Signaling Ameliorates Dermatitis in a Murine Model of Systemic Lupus Erythematosus
Abstract Number: 2283

Suppression of Monosodium Urate (MSU) Crystals-Induced Inflammatory Response By Inhibiting TGF-β Activated Kinase 1 (TAK1)
Abstract Number: 2259

Suppression of Monosodium Urate Crystal-Induced Cytokine Production Via Inhibition of Histone Deacetylases 1/2
Abstract Number: 175

Suppressor of Cytokine Function One (SOCS1) Is Elevated in Non-Classical Monocytes and Correlates with Disease Activity in Systemic Lupus Erythematosus Patients
Abstract Number: 3245

Surfactant Protein D and Krebs Von Den Lungen-6 Predict Severity of Systemic Sclerosis-Related Interstitial Lung Disease in Two Independent Cohorts
Abstract Number: 2949

Surgical Method for Aortic Root Involvement of Behcet Disease
Abstract Number: 1166

Survey on the Understanding and Practice of T2T for Nurses Engaged in Medical Treatment of Rheumatoid Arthritis
Abstract Number: 828

Survival and Health-Related Quality of Life in Incident Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Multicentre Australian Cohort Study
Abstract Number: 910

Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study
Abstract Number: 1641

Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Abstract Number: 2794

Sustained Complete Remission in Lupus Nephritis
Abstract Number: 604

Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study
Abstract Number: 1733

Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis
Abstract Number: 1416

Sustained Improvement in Documentation of Disease Activity Measurement As a Quality Improvement Project at an Academic Rheumatology Clinic
Abstract Number: 3138

Sustained Improvement in Follow-up of Hypertension in Rheumatology Patients: Results of an Intervention Sustainability Assessment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].